Results 101 to 110 of about 1,295 (151)

Design of Novel Derivatives of Phosphonoformate (Foscarnet) as Prodrugs and Antiviral Agents

open access: yes, 2016
Design of Novel Derivatives of Phosphonoformate (Foscarnet) as Prodrugs and Antiviral ...
Colin G. Ferguson (487955)   +2 more
core   +1 more source

Evaluation of Cytomegalovirus Treatment in Transplant Patients Before and During the Foscarnet Nationwide Shortage

open access: yes, 2012
Class of 2012 AbstractSpecific Aims: To compare and evaluate the therapies prescribed, the incidence of adverse drug events, and the time to clinical cure in transplant patients with a cytomegalovirus (CMV) infection at an academic medical center before ...
Leadbetter, Maggie   +4 more
core   +1 more source

Convenient twice daily foscarnet in induction therapy of AIDS associated CMV retinitis

open access: yes, 1997
CAROSI, Giampiero   +4 more
core   +1 more source

Corrigendum: Refractory human cytomegalovirus infection without evidence of genetic resistance in the UL-54 and UL-97 genes in a pediatric hematopoietic stem cell transplant recipient: a case report

open access: yesFrontiers in Medicine
Alejandra Pando-Caciano   +4 more
doaj   +1 more source

Foscarnet Sodium

open access: yesRetina, 1991
Cytomegalovirus (CMV), a major opportunistic viral pathogen frequently causing disease in immunocompromised patients such as organ transplant recipients and people with AIDS, may present as pneumonitis, gastrointestinal disease, or encephalitis. Its most common manifestation in patients with AIDS is retinitis which, if left untreated, invariably ...
J R, Minor, J K, Baltz
openaire   +3 more sources

Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.

open access: yesClinical Infectious Diseases
International audienceAbstract We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2).
Sylvie Lariven   +2 more
exaly   +2 more sources

Foscarnet

Reactions Weekly, 1990
  +4 more sources

Foscarnet

Reactions Weekly, 1992
  +4 more sources

Foscarnet

Reactions Weekly, 2012
  +4 more sources

Home - About - Disclaimer - Privacy